Genomadix announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology. The Genomadix CubeTM uses polymerase chain reaction (PCR) technology in a small and portable footprint to generate timely (one hour), accurate test results, expanding the reach beyond centralized labs.
The Genomadix CubeTM testing system already delivers environmental testing for potentially deadly Legionella bacteria in water sources such as building cooling towers and CYP2C19 genotype guided antiplatelet therapy in Europe with efforts underway for US authorization. Additionally, a COVID-19 product has been developed with introduction slated (pending authorization) for later in 2022.
“We are extremely proud to be collaborating with Mayo Clinic to progress our technology and mission to make highly accurate molecular testing available for the benefit of patients. This collaboration seeks to seed new product developments with focused expertise provided by Mayo Clinic experts” commented Steve Edgett, Genomadix’s CEO
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
Alex Sanchez has an MBA degree specializing in finance. He has extensive knowledge in finance and his deep passion for writing and analysis is well-known for its precision and plenitude. Alex loves reading, classical music, chess, and dogs. He continues to inspire through blogging and writing, focusing on the Business category.
Email: [email protected]
Address: 455 Park Avenue, Worcester, MA 01605, USA
Contact number: 508-462-7042
More Stories
Microsoft’s $1.3 Billion Investment in Mexico: Driving AI and Cloud Infrastructure
Google Avoids Jury Trial in Antitrust Case with $2.3 Million Payment
NHTSA Investigates Amazon’s Zoox Self-Driving Vehicles